Medaphor Group PLC Director Appointment (0049V)
31 October 2017 - 2:19AM
UK Regulatory
TIDMMED
RNS Number : 0049V
Medaphor Group PLC
30 October 2017
MedaPhor Group plc
("MedaPhor" or the "Company")
Director Appointment
MedaPhor Group plc (AIM: MED), the intelligent ultrasound
software and simulation company, announces the appointment of
Andrew Charles Barker as a Non-Executive Director effective
immediately. Upon joining, Andrew will succeed David Baynes as
Chairman of the Remuneration Committee, while David will retain the
Chairmanship of the Company's Audit Committee.
Andrew, 59, has over 30 years' experience in senior management
of technology and software businesses and in venture capital,
having been involved in the early stages of internet computing with
Sun Microsystems in Silicon Valley, later going on to help build
Intel's venture arm in the UK.
He is an experienced NED and investor in early stage companies
with disruptive technology. His portfolio has a med-tech focus and,
in addition to his position as a Director of Intelligent Ultrasound
Limited (acquired by MedaPhor on 6 October 2017, RNS number:
8775S), Andrew is the Chairman of Brainomix, a University of Oxford
medical imaging spin out and a Partner of Anchard Associates
LLP.
Riccardo Pigliucci, Chairman of MedaPhor, said: "I am very
pleased to welcome Andrew to the Board. In addition to bringing a
wealth of relevant experience, his appointment highlights the
importance of Intelligent Ultrasound to the enlarged group and will
facilitate its integration into MedaPhor."
Other than that set out above, there are no other matters that
are required to be disclosed under Schedule 2 paragraph (g) of the
AIM Rules in relation to the appointment of Mr. Barker.
Enquiries:
MedaPhor Group plc www.medaph
or.com
Stuart Gall, CEO Tel: +44 (0) 29
2075
6534
Cenkos Securities Tel: +44 (0) 20
7397
8900
Bobbie Hilliam (Nominated
Advisor)
Michael Johnson / Julian
Morse (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or
medaphor@walbrookpr.com
Paul McManus / Anna Mob: +44 (0)7980 541 893 / Mob:
Dunphy +44 (0)7876 741 001
About MedaPhor (www.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and
simulation company, develops advanced hi-fidelity haptic and
manikin based training simulators, clinical image analysis software
tools, augmented reality based needle guidance software and
artificial intelligence based automated scanning software for all
medical practitioners.
Based in Cardiff and Oxford in the UK and Atlanta in the US,
MedaPhor is split into two divisions:
Ultrasound Simulation and Training
Focuses on hi-fidelity ultrasound education and training through
simulation. Its three main products are the ScanTrainer OBGYN and
General Medical simulator training platform, the HeartWorks
echocardiography simulator platform and the BodyWorks Point-of-Care
simulator platform (launching January 2018). Over 500 MedaPhor
simulators have been sold to over 300 medical institutions in over
30 countries around the world.
Intelligent Ultrasound
Focuses on developing augmented reality and deep-learning based
algorithms to make ultrasound machines smarter and more accessible.
ScanNav uses machine-learning based algorithms to automatically
access and grade ultrasound images to provide scan assessment and
audit of obstetric scanning. NeedleGuide aims to simplify
ultrasound-guided needling by using deep learning and augmented
reality to provide the user with pathway guidance and automated
tracking for a range of medical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAWGGQUUUPMGAU
(END) Dow Jones Newswires
October 30, 2017 11:19 ET (15:19 GMT)
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From Apr 2024 to May 2024
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From May 2023 to May 2024